USNA: Hiya momentum offsets core customer declines as FY2026 adjusted EBITDA guidance falls to ~$77 million

What happened

USANA Health Sciences said its FY2026 guidance is approaching $900 million in net sales and about $77 million in adjusted EBITDA, a measure of earnings before certain costs. Hiya added subscribers and returned to sales growth, while declines among core customers and uneven Rise orders remain headwinds.

Confirmed

Global impact / market context

The outlook points to sales near $900 million but adjusted EBITDA of about $77 million, so earnings may remain limited relative to sales. Hiya’s growth could help offset weakness, but continued core-customer declines or uneven Rise orders could pressure revenue and the company’s ability to cover costs.

Analyst inference

The supplied update describes a mixed business picture: Hiya is growing, but core customers are declining and Rise orders are uneven. For investors, this creates a test of whether growth in one area can offset softness elsewhere and support the stated earnings outlook.

Analyst inference

What to watch

1. Track whether Hiya continues adding subscribers and sustaining sales growth; a reversal would weaken the offset to declines in core customers described in the update. Analyst inference
2. Watch for further company guidance on FY2026 net sales near $900 million and adjusted EBITDA around $77 million, including any change to those outlook figures. Analyst inference
3. Look for signs that core-customer declines ease and Rise orders become less uneven; persistent weakness in either could make the stated outlook harder to achieve. Analyst inference

Evidence

• Original source link unavailable